Note: Ingredients listed on restricted chemical lists
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
General Information
Revision date
2017-11-29
Product name
Oxaliplatin Injection, USP, 50 mg/10mL and 100 mg/20mL
Chemical name
cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N"] [oxalato(2-)- O,O"] platinum
Emergency telephone
855-273-0154
Icons in SDS
Company Information
company name
Athenex Pharmaceutical Division
GHS Information
Signal word
Oxaliplatin
Section 2
SECTION 2: Hazards identification
a)
2.1 Classification of the substance or mixture
Mutagenic, cytotoxic, neurotoxic and fetotoxic. The drug substance is a possible carcinogen and a severe eye irritant.
Signal word
Oxaliplatin injection is an antineoplastic agent and is Hazard statement(s), considered a Hazardous Drug per the NIOSH alert: Symbol(s), and/or Preventing Occupational Exposures to Antineoplastic and Precautionary Other Hazardous Drugs in Health Care Settings. Health care workers who prepare or administer hazardous drugs or who
Hazard statements
work in areas where these drugs are used should follow specific handling guidelines to prevent exposure to these agents in the air or on work surfaces, clothing, medical equipment, or patient urine or feces. See Section 8 for specific handling guidance from the NIOSH Alert for use in the health care setting. (c) Description of Anticipated signs of overexposure include nausea, vomiting, diarrhea, peripheral neurotoxicity (with cold sensitivity and rare laryngeal dysesthesias, sensation of difficulty with breathing or swallowing), and possible myelosuppression (low blood counts). Mucositis (sore mouth, or soreness of other mucous membranes) and transient elevation of liver enzymes have been observed. As with other platinum compounds allergic reactions have been observed. In therapeutic use, very rare anaphylactoid reactions (severe, possibly life-threatening allergic reactions) have been observed. (d) Unknown Acute N/A Toxicity: